Navigation Links
Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
Date:2/22/2008

nfectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug- resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com.

This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for Pneumocystis pneumonia (PCP). Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Immtech Announces Posting of Annual Shareholders Meeting Presentation
2. Immtech Reports Fiscal Second Quarter 2008 Results
3. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Chinese SFDA Grants Immtech Fast Track Status
7. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
8. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
9. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... MOUNTAIN VIEW, Calif. , Oct. 31, 2014 /PRNewswire/ ... amyotrophic lateral sclerosis (ALS) patients initiate text and email ... based upon a patent-pending technology invented by ThynkWare,s founder, ... virtual assistant on a smartphone device. This technology allows ... ways using only the power of thought. ...
(Date:10/31/2014)... 2014 Migranade, Inc. announced today the new ... the 36 million U.S. migraine sufferers November, 2014. The ... the actual cause of migraines and not just the ... the source Migranade is assured to be a game ... is available at http://www.migranade.com and will soon ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Game Changing Migraine Medication To Be Available November 2014 2
... 16, 2011  Senior citizens and people living with physical ... power wheelchairs if the Administration enacts a restrictive prepayment ... Medicare system, according to consumer advocates and home medical ... Centers for Medicare and Medicaid Services (CMS) has listed ...
... 16, 2011  Veran Medical Technologies announced today the ... bi-planar virtual fluoroscopy view used to navigate multiple ... its kind in pulmonology, enabling physicians to view ... in a fluoro-like view without any radiation being ...
Cached Medicine Technology:Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 2Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 3Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 4Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View 2
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... October 31, 2014 Energy Textiles has ... The new gear is now available online, and Energy ... benefits of Celliant infrared-active athletic gear over compression gear. ... another contract has been signed for Under Armour to ... the next eight years. In light of this decision, ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... 2014 Gold Medal Wine Club ... but tasteful gifts for the wine novice and enthusiasts on ... Gift Giving Special , which Early Bird shoppers receive discounts ... Club Gift membership. , Gift Givers must place their ... Besides offering discounts, Gold Medal Wine Club adds more value ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... ( www.PatientAssistance.com ) has released initial survey results on diabetes ... ... Baton Rouge, LA – November 20, 2008 – ... awareness amongst the predominantly uninsured and underinsured visitors of ...
... Amy Rees Anderson, was invited to participate with U.S. Secretary of ... Care. , ... Salt Lake City (Vocus) November 20, ... with U.S. Secretary of Health, Michael Leavitt, in the 2008 National ...
... for the prestigious "Super Dentist" award given to elite dentists in ... top practitioner in the area of Cosmetic Dentistry. , ... ... Austin Smiles was recently nominated as a "Texas Monthly ...
... the frequency of exacerbations in patients with moderate to ... as 35 percent, according to a London-based study. ... macrolide therapy, reducing exacerbation frequency and severity with moderate ... Terence A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D., ...
... NEW YORK Nov. 19, 2008 The American ... and largest non-governmental funder of cancer research and discovery ... Honor, to four Americans who have made outstanding contributions ... will receive their awards at a ceremony during the ...
... says about 40% returned positive results in review of ... Colorectal cancer screening detects 40 percent of cancers and ... Finnish Cancer Registry researchers. , They studied 106,000 people, ... colorectal cancer screening program was in identifying unrecognized disease. ...
Cached Medicine News:Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Scientists honored for contributions to cancer fight 2Health News:Scientists honored for contributions to cancer fight 3Health News:Scientists honored for contributions to cancer fight 4Health News:Scientists honored for contributions to cancer fight 5Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Medicine Products: